Evidence map›Paper›PMID 42462595›Full record

ArticleCytotherapy2026

A 38-color spectral panel for cost efficient characterization of T cell therapy products.

Gage D Paul, Imani A Hall, Patrick J Hanley, Catherine M Bollard, Christopher A Lazarski

Abstract read
In one paragraph

Article in Cytotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gage D PaulCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.
Imani A HallCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.
Patrick J HanleyCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA; George Washington University, Washington, District of Columbia, USA.
Catherine M BollardCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA; George Washington University, Washington, District of Columbia, USA; Cancer Research Center, Fralin Biomedical Research Institute at VTC, Children's National Research and Innovation Campus, Washington, District of Columbia, USA.
Christopher A LazarskiCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA; George Washington University, Washington, District of Columbia, USA; Cancer Research Center, Fralin Biomedical Research Institute at VTC, Children's National Research and Innovation Campus, Washington, District of Columbia, USA. Electronic address: clazarsk@childrensnational.org.

Funding

NextGen - CRIOT2CA278700 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI Catherine M. Bollard · 2022 to 2026
$5.6M
NCI NIH HHS OT2 CA278700
6 · The paper itself

Abstract

Investigators must frequently apportion precious sample volumes between multiple assays to measure the viability, potency, and compositional phenotype of cell therapy products and clinical research samples. However, the use of disparate assay modalities may miss critical information which links the expression profile of cells with functional activity, especially when these activated cell populations are rare. To address this shortcoming, we describe in this short report the creation of a 38-color spectral flow cytometry panel for the phenotypic and functional characterization of antigen reactive T cell populations within cellular therapy products and clinical research samples. Our investigations identified that up to 29 potentially co-expressing markers were able to be identified on mixed sample populations using this panel, including phenotype, activation, and exhaustion markers, as well as intracellular cytokine production. Our calculations also highlight spectral flow cytometry is a more efficient use of technician time, reagent cost, and product sample usage as compared with an equivalent set of traditional flow cytometry panels.

Indexed as

Cell- and Tissue-Based TherapyFlow CytometryImmunotherapy, AdoptiveT-LymphocytesHumansImmunophenotypingLymphocyte Activationadoptive immunotherapycell manufacturingcost analysishigh parameter flow cytometryspectral flow cytometryT cell immunotherapy

Identifiers

PMID42462595
PMCPMC13505791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.